200 related articles for article (PubMed ID: 32643793)
1. Therapeutic applications of chelating drugs in iron metabolic disorders of the brain and retina.
Shahandeh A; Bui BV; Finkelstein DI; Nguyen CTO
J Neurosci Res; 2020 Oct; 98(10):1889-1904. PubMed ID: 32643793
[TBL] [Abstract][Full Text] [Related]
2. Iron chelation and neuroprotection in neurodegenerative diseases.
Li X; Jankovic J; Le W
J Neural Transm (Vienna); 2011 Mar; 118(3):473-7. PubMed ID: 21161300
[TBL] [Abstract][Full Text] [Related]
3. Iron: a new target for pharmacological intervention in neurodegenerative diseases.
Whitnall M; Richardson DR
Semin Pediatr Neurol; 2006 Sep; 13(3):186-97. PubMed ID: 17101458
[TBL] [Abstract][Full Text] [Related]
4. The potential application of iron chelators for the treatment of neurodegenerative diseases.
Hider RC; Roy S; Ma YM; Le Kong X; Preston J
Metallomics; 2011 Mar; 3(3):239-49. PubMed ID: 21344071
[TBL] [Abstract][Full Text] [Related]
5. Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
Devos D; Cabantchik ZI; Moreau C; Danel V; Mahoney-Sanchez L; Bouchaoui H; Gouel F; Rolland AS; Duce JA; Devedjian JC;
J Neural Transm (Vienna); 2020 Feb; 127(2):189-203. PubMed ID: 31912279
[TBL] [Abstract][Full Text] [Related]
6. Neurodegenerative diseases and therapeutic strategies using iron chelators.
Ward RJ; Dexter DT; Crichton RR
J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
[TBL] [Abstract][Full Text] [Related]
7. Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.
Bergsland N; Tavazzi E; Schweser F; Jakimovski D; Hagemeier J; Dwyer MG; Zivadinov R
CNS Drugs; 2019 Nov; 33(11):1073-1086. PubMed ID: 31556017
[TBL] [Abstract][Full Text] [Related]
8. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Youdim MB; Stephenson G; Ben Shachar D
Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities.
Weinreb O; Amit T; Mandel S; Kupershmidt L; Youdim MB
Antioxid Redox Signal; 2010 Sep; 13(6):919-49. PubMed ID: 20095867
[TBL] [Abstract][Full Text] [Related]
10. Green tea catechins as brain-permeable, non toxic iron chelators to "iron out iron" from the brain.
Mandel S; Weinreb O; Reznichenko L; Kalfon L; Amit T
J Neural Transm Suppl; 2006; (71):249-57. PubMed ID: 17447435
[TBL] [Abstract][Full Text] [Related]
11. The role of iron in brain ageing and neurodegenerative disorders.
Ward RJ; Zucca FA; Duyn JH; Crichton RR; Zecca L
Lancet Neurol; 2014 Oct; 13(10):1045-60. PubMed ID: 25231526
[TBL] [Abstract][Full Text] [Related]
12. Mini-Review: Is iron-mediated cell death (ferroptosis) an identical factor contributing to the pathogenesis of some neurodegenerative diseases?
Viktorinova A; Durfinova M
Neurosci Lett; 2021 Feb; 745():135627. PubMed ID: 33440237
[TBL] [Abstract][Full Text] [Related]
13. Iron Chelation in Movement Disorders: Logical or Ironical.
Kulshreshtha D; Ganguly J; Jog M
Can J Neurol Sci; 2021 Nov; 48(6):752-759. PubMed ID: 33397531
[TBL] [Abstract][Full Text] [Related]
14. Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities.
Merelli A; RodrÃguez JCG; Folch J; Regueiro MR; Camins A; Lazarowski A
Curr Neuropharmacol; 2018; 16(10):1484-1498. PubMed ID: 29318974
[TBL] [Abstract][Full Text] [Related]
15. Iron chelating strategies in systemic metal overload, neurodegeneration and cancer.
Gumienna-Kontecka E; Pyrkosz-Bulska M; Szebesczyk A; Ostrowska M
Curr Med Chem; 2014; 21(33):3741-67. PubMed ID: 25005181
[TBL] [Abstract][Full Text] [Related]
16. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic approach for neurodegenerative pathologies: multitarget iron-chelating drugs regulating hypoxia-inducible factor 1 signal transduction pathway.
Weinreb O; Amit T; Mandel S; Youdim MB
Neurodegener Dis; 2012; 10(1-4):112-5. PubMed ID: 22156453
[TBL] [Abstract][Full Text] [Related]
18. Iron chelation in the treatment of neurodegenerative diseases.
Dusek P; Schneider SA; Aaseth J
J Trace Elem Med Biol; 2016 Dec; 38():81-92. PubMed ID: 27033472
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance.
Liu G; Men P; Harris PL; Rolston RK; Perry G; Smith MA
Neurosci Lett; 2006 Oct; 406(3):189-93. PubMed ID: 16919875
[TBL] [Abstract][Full Text] [Related]
20. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders.
Mandel S; Amit T; Reznichenko L; Weinreb O; Youdim MB
Mol Nutr Food Res; 2006 Feb; 50(2):229-34. PubMed ID: 16470637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
